Executive Director, Head of Rare Cancer @AstraZeneca @Alexion Former Professor @Harvardmed Firm to find CURE for #RareCancer #GBM #DIPG #Sarcoma
Boston, MA
Joined September 2018
- Tweets838
- Following270
- Followers797
- Likes1.6K
May is Brain Tumor Awareness Month.
@AstraZeneca and @AlexionPharmaUS , we are committed to advancing rare oncology research—including brain tumors—where innovation can make the greatest impact on patients and families.
#BrainTumorAwareness #RareDisease #Oncology #Innovation
Bakhos A. Tannous, PhD retweeted
Online Now: Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity dlvr.it/TSKVFp
Bakhos A. Tannous, PhD retweeted
Online Now: A photoreceptor state links aggressive brain tumors in children dlvr.it/TRbCvd
Bakhos A. Tannous, PhD retweeted
CAR T cells are laboratory-engineered immune cells that provide effective treatment for some cancers. Progress is being made towards creating these cells in vivo
go.nature.com/3NtYGY4
#Thanksgiving is not only to be greatful for all the "good" in our life, but also reflect on the “bad" and recommit our energies to giving thanks and just "#giving". Happy and blessed thanksgiving to everyone who celebrates it
Bakhos A. Tannous, PhD retweeted
The role of ultra-processed food (UPF) in obesity | @NatureRevEndo —time to sound the alarm 🚨 on UPF! Nice review that focus on the biological link between UPF and Obesity nature.com/articles/s41574-0…
Bakhos A. Tannous, PhD retweeted
Pan-cancer human brain metastases atlas at single-cell resolution dlvr.it/TLw4ZN
Bakhos A. Tannous, PhD retweeted
In the latest issue! Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis dlvr.it/TLv0mQ
Bakhos A. Tannous, PhD retweeted
Recent research found that #temozolomide rechallenge is a common, safe, and effective second-line option for patients with MGMT-methylated, #IDHwildtype #GBM following first-line lomustine/temozolomide therapy.
Read the full article in our latest issue: bit.ly/4497BUq
Bakhos A. Tannous, PhD retweeted
Policy Corner by Abdullah H. Ishaque, MD, PhD (@ahishaque), @AbdiAidid, JD, LLM, and @gelarehzadeh, MD, PhD: Lessons from the Failure of Canada’s Artificial Intelligence and Data Act nejm.ai/4ekfI3Q
#AIinMedicine
ALT Page 1 of the Policy Corner article "Lessons from the Failure of Canada’s Artificial Intelligence and Data Act"
Bakhos A. Tannous, PhD retweeted
Super excited to share our newest piece out today @NatureRevCancer linking age-induced metabolic reprogramming to cancer development. nature.com/articles/s41568-0…
🟡 July is #sarcomaawarenessmonth 🟡
Sarcoma is a rare and often overlooked cancer, but its impact is deeply felt by every patient and family it touches. @AstraZeneca and @AlexionPharmaUS, we are committed to transforming outcomes for patients with rare cancers like #sarcoma
Bakhos A. Tannous, PhD retweeted
The more potent and bespoke immunotherapy vs cancer, the better. Today's example is a neoantigen vaccine vs melanoma
cell.com/cell/fulltext/S0092…
Bakhos A. Tannous, PhD retweeted
Online Now: KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer dlvr.it/TLrhCk
I'm happy to share that I’ve started a new position as Executive Director, Head of Rare Cancer Discovery @AstraZeneca and @AlexionPharmaUS
Looking forward to what’s ahead!
Bakhos A. Tannous, PhD retweeted
Online now: Niche-specific therapeutic targeting of myeloid cells in the central nervous system dlvr.it/TKYNlp
Bakhos A. Tannous, PhD retweeted
Good update of recommendation for LGG management in the era of vorssidenib. More trials in progress
@EANOassociation
@EORTC
@SapienzaRoma
@ESTRO_RT
@myESMO
